Biohaven/Pfizer Partnered Rimegepant Asia-Pacific Migraine Trial Meets Primary Endpoints

Biohaven Pharmaceutical Holding Company Ltd BHVN and Pfizer Inc PFE reported topline results from an Asia-Pacific, Phase 3 trial of rimegepant in adults for the acute treatment of migraine. 

  • The study met its co-primary endpoints of freedom from pain and freedom from most bothersome migraine-associated symptom, including either nausea, phonophobia, or photophobia at 2-hours following a single oral dose of rimegepant.
  • In the study, a single oral dose of rimegepant 75 mg provided significant relief of migraine symptoms and return to normal function at 2 hours and delivered sustained efficacy that lasted up to 48 hours for many patients. 
  • Related: Biohaven's Zavegepant Pain Spray Aces Late-Stage Migraine Trial.
  • Rimegepant showed a favorable safety and tolerability profile, the company said.
  • Pfizer has commercialization rights to rimegepant in markets outside of the U.S. Biohaven continues to lead research and development globally and retains the U.S. market. 
  • Rimegepant is commercialized as Nurtec ODT in the U.S. and is the only oral CGRP receptor antagonist approved for acute and preventive migraine treatment in adults. 
  • Rimegepant application is currently under review by the European Medicines Agency, with a decision expected in 1H of 2022. 
  • Price Action: PFE stock is down 1.26% at $50.14 during the premarket session on the last check Monday. BHVN closed at $134.84 on Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsmigrainePhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!